Real-world data on brodalumab affirm efficacy and fast onset of action

A German study investigated the performance of brodalumab for the treatment of psoriasis in real-world conditions. They found meaningful responses as of week 2 and the highest clearance rates in biologic-naïve patients. In clinical phase 3 trials, brodalumab was shown to have remarkable efficacy and early commencing action in psoriasis patients. The authors aim to assess this translates into a patient population encountered in daily practice [1]. The ongoing, prospective, non-interventional study investigates the real-world evidence of brodalumab in disease management of psoriasis after 12 and 52 weeks. Data was obtained between November 2017 and January 2020 from 216 German study centres on the effect of brodalumab on the absolute psoriasis area severity index (aPASI) of over 500 patients. Dr Ralph Von Kiedrowski (Germany) presented the 12-week results of the study at the EADV Congress. Mean age of study subjects was 50, mean duration of disease 20...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 October, 202018 December, 2020